Waters (NYSE:WAT) Price Target Raised to $410.00

Waters (NYSE:WAT) had its price objective increased by stock analysts at TD Cowen from $363.00 to $410.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the medical instruments supplier’s stock. TD Cowen’s price objective would suggest a potential upside of 6.76% from the stock’s previous close.

WAT has been the topic of several other reports. Leerink Partnrs raised Waters from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Stifel Nicolaus boosted their price target on Waters from $332.00 to $360.00 and gave the company a “hold” rating in a research note on Monday. Leerink Partners raised Waters from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $325.00 to $375.00 in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price target on Waters from $340.00 to $380.00 and gave the company a “neutral” rating in a research note on Monday. Finally, The Goldman Sachs Group raised Waters to a “hold” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Waters presently has an average rating of “Hold” and a consensus price target of $364.69.

Waters Trading Down 0.8 %

Shares of Waters stock traded down $3.17 during midday trading on Monday, reaching $384.04. The company had a trading volume of 384,099 shares, compared to its average volume of 429,061. The stock has a fifty day moving average price of $342.04 and a 200 day moving average price of $325.28. The company has a debt-to-equity ratio of 1.42, a current ratio of 2.10 and a quick ratio of 1.42. The firm has a market cap of $22.80 billion, a PE ratio of 36.66, a P/E/G ratio of 6.35 and a beta of 0.97. Waters has a fifty-two week low of $241.95 and a fifty-two week high of $391.00.

Waters (NYSE:WAT) last posted its quarterly earnings data on Friday, November 1st. The medical instruments supplier reported $2.93 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.25. The company had revenue of $740.30 million for the quarter, compared to analyst estimates of $712.99 million. Waters had a return on equity of 56.81% and a net margin of 20.71%. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 earnings per share. On average, equities analysts anticipate that Waters will post 11.6 earnings per share for the current year.

Institutional Investors Weigh In On Waters

Several institutional investors have recently bought and sold shares of WAT. Itau Unibanco Holding S.A. bought a new position in Waters in the 2nd quarter valued at $33,000. Blue Trust Inc. grew its stake in Waters by 190.2% in the 2nd quarter. Blue Trust Inc. now owns 119 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 78 shares during the period. TFC Financial Management Inc. grew its stake in Waters by 19,900.0% in the 2nd quarter. TFC Financial Management Inc. now owns 200 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 199 shares during the period. Federated Hermes Inc. bought a new position in Waters in the 2nd quarter valued at $59,000. Finally, Fidelis Capital Partners LLC bought a new position in Waters in the 1st quarter valued at $72,000. Institutional investors own 94.01% of the company’s stock.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.